Drug Profile
Research programme: cancer therapeutics - RESprotect
Alternative Names: RP-656; RP-701; RP-885Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator RESprotect
- Class Small molecules
- Mechanism of Action Apoptosis stimulants; HSP27 heat shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for preclinical development in Cancer in Germany (PO)
- 21 Jun 2018 Preclinical development is ongoing in Cancer in Germany (PO) (RESprotect pipeline, June 2018)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Germany (PO)